Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells

Cell Research

Volumn 18, Issue 8, 2008, Pages 879-888

  Mao, Xin ^a   Rong Yu, Chun ^a   Hua Li, Wen ^a   Xin Li, Wen ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cytochrome c; JNK; ROS; Shikonin

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; CASPASE; CYTOCHROME C; NAPHTHOQUINONE; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; SHIKONIN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CYTOCHROMES C; FUSION PROTEINS, BCR-ABL; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOCHONDRIA; NAPHTHOQUINONES; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 49149088537     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2008.86     Document Type: Article

References (40)

1. Shen N, ed. Shen Nong Ben Cao Jing. Lanzhou: Lanzhou University Press, 2004.
2. Li SZ, ed. Ben Cao Gang Mu. Chongqing: Chongqing University Press, 1994.
3. Staniforth V, Wang SY, Shyur LF, et al. Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibits the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. J Biol Chem 2004; 279:5877-5885.
4. Shen CC, Syu JJ, Li YY, et al. Antimicrobial activities of naphthazarins from Arnebia euchroma. J Nat Prod 2002; 65:1857-1862.
5. Singh B, Sharma MK, Meghwal PR, et al. Anti-inflammatory activity of shikonin derivatives from Arnebia hispidissima. Phytomedicine 2003; 10:375-380.
6. Chen X, Oppenheim J, Howard OM. Shikonin, a component of anti-inflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1. Int Immunopharmacol 2001; 1:229-236.
7. Sankawa U, Ebizuka Y, Miyazaki T, et al. Antitumor activity of shikonin and its derivatives. Chem Pharm Bull 1977; 25:2392-2395.
8. Sankawa U, Otsuka H, Kataoka Y, et al. Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. Chem Pharm Bull 1981; 29:116-122.
9. Gao D, Hiromura M, Yasui H, et al. Direct reaction between shikonin and thiols induces apoptosis in HL60 cells. Biol Pharm Bull 2002; 25:827-832.
10. Hashimoto S, Xu M, Masuda Y, et al. β-Hydroxyisovaler ylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells through a mechanism different from those of Fas and etoposide. J Biochem 1999; 125:17-23.
11. Hsu PC, Huang YT, Tsai ML, et al. Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 2004; 52:6330-6337.
12. Chen CH, Chern CL, Lin CC, et al. Involvement of reactive oxygen species, but not mitochondrial permeability transition in the apoptotic induction of human SK-Hep-1 hepatoma cells by shikonin. Planta Med 2003; 69:1119-1124.
13. Singh F, Gao D, Lebwohl MG, et al. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett 2003; 200:115-121.
14. Wu Z, Wu L, Li L, et al. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 2004; 94:166-176.
15. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-293.
16. Bartram CR, Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306:277-280.
17. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21:8541-8546.
18. Gorre ME, Mohammed M, Ellwood K. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
19. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
20. Kerr JFR, Wyllie AH, Currie AR, et al. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
21. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308.
22. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76:959-962.
23. Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15:269-290.
24. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15:2922-2933.
25. Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86:147-157.
26. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275:1129-1132.
27. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13:1899-1911.
28. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33-42.
29. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16:444-454.
30. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192:1-15.
31. Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000; 49:427-435.
32. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7:97-110.
33. Kanda H, Miura M. Regulatory roles of JNK in programmed cell death. J Biochem (Tokyo) 2004; 136:1-6.
34. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288:870-874.
35. Kharbanda S, Saxena S, Yoshida K, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem 2000; 275:322-327.
36. Donovan N, Becker EB, Konishi Y. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002; 277:40944-40949.
37. Putcha GV, Le S, Frank S, et al. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003; 38:899-914.
38. Herrant M, Jacquel A, Marchetti S, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23:7863-7873.
39. Yu CR, Mao X, Li WX. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005; 331:391-397.
40. Bass DA, Parce JW, Dechatelet LR. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983; 130:1910-1917.